Effects of exercise on immune function in lymphoma patients
The Effects of Acute and Chronic Exercise on the Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients
NA · Mayo Clinic · NCT05876923
This study tests how short-term and long-term exercise affects the immune system and overall well-being of patients with certain types of lymphoma.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 70 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Mayo Clinic (other) |
| Locations | 2 sites (Scottsdale, Arizona and 1 other locations) |
| Trial ID | NCT05876923 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates how both short-term and long-term exercise impacts the immune characteristics of patients with indolent non-Hodgkin lymphoma and chronic lymphocytic leukemia. The study aims to assess the response of immune cells to acute exercise and a 12-week exercise training program, comparing these responses to age-matched controls. It also evaluates the effectiveness of exercise in reducing cancer-related side effects and improving quality of life and physical fitness. Additionally, the study will develop an AI system to optimize exercise training results for these patients.
Who should consider this trial
Good fit: Ideal candidates include English-speaking adults aged 18-80 with a histologically confirmed diagnosis of indolent non-Hodgkin lymphoma or chronic lymphocytic leukemia.
Not a fit: Patients with significant cardiovascular or pulmonary diseases, orthopedic limitations, or those currently undergoing treatment may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance immune function and overall health in patients with indolent lymphomas, potentially improving survival and quality of life.
How similar studies have performed: Other studies have shown promising results with exercise interventions in cancer patients, suggesting potential benefits in immune function and quality of life.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * English speaking * Between the ages of 18-80 * Histologically confirmed diagnosis of indolent non-Hodgkin lymphoma (NHL) will be required to participate in Aim 2 (CLL/SLL only), aim 3 and 4 (indolent NHL) and aim 5 (indolent NHL) of this study Exclusion Criteria: * Healthy subjects participating in Aim 1 will be excluded if they have known cardiovascular or pulmonary disease (e.g. heart disease, coronary artery disease, chronic obstructive pulmonary disease \[COPD\], asthma, etc.) an orthopedic or musculoskeletal limitation which would limit ability to exercise or are a current or former smoker * Indolent NHL individuals receiving treatment must have least 8 weeks of planned treatment remaining and those who have already received treatment must be at least 6 months post and have no planned treatments during the 12-week intervention period to be eligible. Individuals that are participating prior to receiving treatment must not have any scheduled treatments during their participation. Individuals will be excluded if they have uncontrolled hypertension, cardiac illness, or are not approved by their oncologist to participate
Where this trial is running
Scottsdale, Arizona and 1 other locations
- Mayo Clinic in Arizona — Scottsdale, Arizona, United States (RECRUITING)
- Mayo Clinic in Rochester — Rochester, Minnesota, United States (RECRUITING)
Study contacts
- Principal investigator: Michael P. Gustafson, PhD — Mayo Clinic
- Study coordinator: Clinical Trials Referral Office
- Email: mayocliniccancerstudies@mayo.edu
- Phone: 855-776-0015
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent Non-hodgkin Lymphoma